Page 4,974«..1020..4,9734,9744,9754,976..4,9804,990..»

Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Current …

Posted: Published on August 15th, 2013

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN) today announced the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with RCHOP (A+RCHOP), the current standard frontline therapy, for newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). The study is intended to evaluate the complete remission rate and safety of the A+RCHOP regimen. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS is currently not approved for the treatment of DLBCL. The encouraging data we have observed in our phase 2 trial of ADCETRIS in relapsed non-Hodgkin lymphoma, including DLBCL patients, support evaluation in earlier lines of therapy for patients with this aggressive lymphoma type, said Clay B. Siegall., Ph.D., President and Chief Executive Officer at Seattle Genetics. This trial will provide us with data on the tolerability of the combination, as well as the antitumor activity achieved by adding ADCETRIS to the current standard frontline regimen. In addition, based on interim findings from our trial in the relapsed setting in which objective responses were observed among patients with low or undetectable levels of CD30 by conventional screening methods, we will enroll high-risk DLBCL patients to this frontline trial without prescreening for CD30 expression. In … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Current …

Fate Therapeutics files for IPO

Posted: Published on August 15th, 2013

LA JOLLA Fate Therapeutics became the latest biotech filing for an IPO on Wednesday. Fate seeks to raise up to $69 million, according to an Xconomy article on the IPO filing. Founded on stem cell technology, the company is in Phase 2 trials of a treatment it calls ProHema to improve the success of hematopoietic stem cell transplants, also called bone marrow transplants. These transplants are often performed on patients whose own blood-forming stem cells have been destroyed by chemotherapy for blood cancers such as leukemia and lymphoma. ProHema is used with stem cells taken from umbilical cord blood. Fate says it will use the proceeds to advance ProHema and its other products in preclinical development, and for general corporate purposes. Fate has been granted orphan designation for ProHema, also called, FT1050, the prospectus states. Fate says it has paused enrollment in the Phase 2 trial because it has developed a better formulation. Preclinical studies show the new formula more than doubles the success rate of engraftment, according to the prospectus. On Aug. 1, Fate submitted an amendment to its IND to the U.S. Food and Drug Administration, asking to use the improved product. "Subject to the consent of the … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Fate Therapeutics files for IPO

Dr P V Mahajan Interview on Stem Cell Treatment for Orthopedic Conditions

Posted: Published on August 15th, 2013

Dr P V Mahajan Interview on Stem Cell Treatment for Orthopedic Conditions Anti Aging Benefits of Stem Cells Anti Aging Treatment 1Stem Cells from your own body are used 2No chemicals or drugs are needed 3Better breathing and sleeping pattern.... By: StemRx BioScience … Continue reading →

Comments Off on Dr P V Mahajan Interview on Stem Cell Treatment for Orthopedic Conditions

Medistem Announces Patent Application on Stem Cell Secreted Nanoparticles (Exosomes)

Posted: Published on August 15th, 2013

SAN DIEGO, CA--(Marketwired - Aug 15, 2013) - Medistem, Inc. (PINKSHEETS: MEDS), announced today the publication of a patent application entitled "Therapeutic Immune Modulation by Stem Cell Secreted Exosomes."The patent application covers the use of stem cell derived nanoparticles, termed "exosomes", for the treatment of autoimmune conditions, including Type 1 Diabetes, multiple sclerosis, rheumatoid arthritis, and lupus. "The data presented in the patent application provides additional insight into the mechanism by which our lead product, Endometrial Regenerative Cell (ERC-124), suppresses autoimmunity in animal models of multiple sclerosis and Type 1 diabetes," said Thomas E. Ichim, Ph.D., President and Chief Scientific Officer of Medistem and co-inventor of the patent application. "Our greater understanding of the mechanism of action of ERC-124 on the immune system, will contribute to our planned FDA submission of an Investigational New Drug (IND) to treat Type 1 Diabetes with our product." The Company has previous published clinical proof of concept data in the in the field of autoimmunity.The Company reported four multiple sclerosis patients treated with ERC-124 in a peer-reviewed publication that can be found at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2649897/pdf/1479-5876-7-15.pdf). "The data and intellectual property presented in the patent application supports the potential of using ERC-124 generated exosomes as an … Continue reading →

Comments Off on Medistem Announces Patent Application on Stem Cell Secreted Nanoparticles (Exosomes)

Bill filed to regulate stem cell therapy in PH

Posted: Published on August 14th, 2013

By Christian V. Esguerra Philippine Daily Inquirer La Union Rep. Eufranio Eriguel. Photo from congress.gov.ph MANILA, PhilippinesA congressman has joined the call to regulate stem cell therapy administered in the country. La Union Rep. Eufranio Eriguel has introduced House Bill No. 212, which would put up a bioethics advisory board that would establish ethical standards governing the practice of stem cell research and therapy. Under the proposed Stem Cell Research and Therapy Act of 2013, the board shall be responsible for addressing contentious ethical, scientific and legal issues in stem cell and cell-based or cellular research and therapies. There is much to be learned from stem cell therapy, its benefits and application in the cure of some of the most devastating diseases and conditions. As of now, the full promise of stem cell treatment remains unknown, Eriguel said in a statement. But the cost far outweighs its benefits because it is very expensive and only a few physicians are trained to do stem cell procedures here in the Philippines. In his proposal, the board will be headed by the health secretary and the National Transplant Ethics Committee, while the Food and Drug Administration director will serve as vice chairman. A … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Bill filed to regulate stem cell therapy in PH

FDA Approves Stem Cell Clinical Trial For Multiple Sclerosis

Posted: Published on August 14th, 2013

NEW YORK, Aug. 14, 2013 /PRNewswire/ --The Tisch MS Research Center of New York announced today that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) to commence a Phase 1 trial using autologous neural stem cells in the treatment of multiple sclerosis (MS). MS is a chronic human autoimmune disease of the central nervous system that leads to myelin damage and neurodegeneration and affects approximately 2.1 million people worldwide. "To my knowledge, this is the first FDA-approved stem cell trial in the United States to investigate direct injection of stem cells into the cerebrospinal fluid of MS patients, and represents an exciting advance in MS research and treatment," said Dr. Saud A. Sadiq, Senior Research Scientist at Tisch MS Research Center of New York and the study's principal investigator. The groundbreaking study will investigate a regenerative strategy using stem cells harvested from the patient's own bone marrow. These stem cells will be injected intrathecally (into the cerebrospinal fluid surrounding the spinal cord) in 20 participants who meet the inclusion criteria for the trial. This will be an open label safety and tolerability study. All study activities will be conducted at the Tisch MS … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on FDA Approves Stem Cell Clinical Trial For Multiple Sclerosis

Explaining Retinitis Pigmentosa, RP – Video

Posted: Published on August 14th, 2013

Explaining Retinitis Pigmentosa, RP This is my best description I can give of retinitis pigmentosa to the onlooker or bystander, so to speak, if you will. I hope it helps and brings a better un... By: Sage Walsh … Continue reading →

Posted in Retinitis Pigmentosa | Comments Off on Explaining Retinitis Pigmentosa, RP – Video

Casino mogul Steve Wynn donates $25 million to find cure for eye disease he has

Posted: Published on August 14th, 2013

IOWA CITY, Iowa Las Vegas casino mogul Steve Wynn will donate $25 million to the University of Iowa to accelerate the search for cures to rare eye diseases including the one that hampers his own vision, the school announced Thursday. The donation, to be paid over five years, will support the Institute for Vision Research, will be renamed in honor of the billionaire chairman and CEO of Wynn Resorts Ltd. The institute is a leader in genetic testing for eye disease and seeks to develop gene and stem cell therapies that could restore vision. Wynn, 71, has retinitis pigmentosa, a disease that affects one in 4,000 people and causes night blindness and weakness in peripheral vision. A fixture at Las Vegas galas, he's often seen leaning on an aide's arm at nighttime events. "As a person who knows firsthand what it is like to lose vision from a rare inherited eye disease, I want to do everything I can to help others who are similarly affected," he said in a statement. "I am thrilled by the pace of the scientific progress that has occurred in the past few years and I feel that the prospect of finding a cure is … Continue reading →

Posted in Retinitis Pigmentosa | Comments Off on Casino mogul Steve Wynn donates $25 million to find cure for eye disease he has

RiverDogs Donate $20,000 to MUSC Storm Eye Institute

Posted: Published on August 14th, 2013

August 9, 2013 - South Atlantic League (SAL) Charleston RiverDogs CHARLESTON, SC - The Charleston RiverDogs have yet again left a large paw print on the fight against blindness and retinitis pigmentosa. During the Friday, August 9 contest against the Rome Braves at Joseph P. Riley, Jr. Park, RiverDogs General Manager Dave Echols will present a check for $20,000 to the Medical University of South Carolina (MUSC) Storm Eye Institute and its director, Dr. Lucian Del Priore. The donation comes from proceeds from the RiverDogs' 14th annual Kindness Beats Blindness Auction, the 10th Annual "Run Forrest Run" 5K, the 9thAnnual Hot Stove Banquet and the 8 th Annual Golf Outing. The Storm Eye Institute was selected as a result of RiverDogs President Mike Veeck's daughter, Rebecca, being diagnosed with retinitis pigmentosa, a group of inherited diseases causing retinal degeneration. Veeck and his wife, Libby, have dedicated themselves and most of their charitable efforts toward fighting blindness. "To work hand-in-hand with the Charleston community for the Storm Eye Institute is something we, as an organization, really look forward to every year," said Echols. "Seeing first-hand the effect this disease can have on a family adds a level of personality and affection … Continue reading →

Posted in Retinitis Pigmentosa | Comments Off on RiverDogs Donate $20,000 to MUSC Storm Eye Institute

Amarantus BioScience – “Ophthalmology: MANF’s Orphan Strategy Coming into Focus in Retinitis Pigmentosa”

Posted: Published on August 14th, 2013

Amarantus BioScience, Inc. (AMBS) today published a new blog post on The Chairmans Blog, written by the companys President and CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. Amarantus President and CEO, Gerald Commissiong, blogs about the companys lead therapeutic program, MANF, and its orphan strategy in the ophthalmology field. He stresses, among other things, the successful company strategies hes seen; A prime example of a successful orphan strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1B buyout by Sanofi Aventis (SNY) in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, who was successfully acquired by Shire (SHPG) for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals (ALXN) reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe. Read the full blog post on TheChairmansBlog.com (http://www.thechairmansblog.com/gerald-commissiong/2013-08/ophthalmology-manfs-orphan-strategy-coming-into-focus-in-retinitis-pigmentosa.html). About Amarantus BioScience, Inc. AmarantusBioScience, Inc. is a development-stage biotechnology company founded in January 2008. The … Continue reading →

Posted in Retinitis Pigmentosa | Comments Off on Amarantus BioScience – “Ophthalmology: MANF’s Orphan Strategy Coming into Focus in Retinitis Pigmentosa”

Page 4,974«..1020..4,9734,9744,9754,976..4,9804,990..»